Cosmo Pharmaceuticals N.V. (CMOPF)
USD 55.0
(0.0%)
USD 55.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.14 Million EUR | -56.22% |
| 2022 | 28.39 Million USD | 133.16% |
| 2021 | 12.17 Million USD | 851.88% |
| 2020 | 1.27 Million USD | 108.53% |
| 2019 | -15 Million USD | 26.84% |
| 2018 | -20.5 Million EUR | -78.66% |
| 2017 | -11.47 Million EUR | -144.79% |
| 2016 | 25.62 Million EUR | 540.28% |
| 2015 | -5.81 Million EUR | -126.2% |
| 2014 | 22.21 Million EUR | 71.7% |
| 2013 | 12.93 Million EUR | -51.21% |
| 2012 | 26.52 Million EUR | 197.71% |
| 2011 | 8.9 Million EUR | 64.57% |
| 2010 | 5.41 Million EUR | -5.58% |
| 2009 | 5.73 Million EUR | -54.33% |
| 2008 | 12.55 Million EUR | 1918.17% |
| 2007 | 622 Thousand EUR | -73.62% |
| 2006 | 2.35 Million EUR | 46.55% |
| 2005 | 1.6 Million EUR | 372.25% |
| 2004 | -591 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 46.57 Million USD | 0.0% |
| 2024 Q1 | 46.91 Million USD | 9000.1% |
| 2023 Q2 | 7.37 Million USD | 90.81% |
| 2023 FY | 12.43 Million USD | -56.22% |
| 2023 Q4 | -2.28 Million USD | -341.59% |
| 2023 Q3 | -516.43 Thousand USD | -107.01% |
| 2023 Q1 | 3.86 Million USD | -80.9% |
| 2022 FY | 28.39 Million USD | 133.16% |
| 2022 Q4 | 20.22 Million USD | 106.95% |
| 2022 Q3 | 9.77 Million USD | 28.69% |
| 2022 Q2 | 7.59 Million USD | 0.0% |
| 2021 FY | 12.17 Million USD | 851.88% |
| 2021 Q4 | 12.21 Million USD | 0.0% |
| 2021 Q2 | -183.53 Thousand USD | 0.0% |
| 2020 Q2 | -3.22 Million USD | 0.0% |
| 2020 FY | 1.27 Million USD | 108.53% |
| 2020 Q4 | 4.77 Million USD | 0.0% |
| 2019 Q4 | 5 Million USD | 0.0% |
| 2019 FY | -15 Million USD | 26.84% |
| 2019 Q2 | -20.24 Million USD | 0.0% |
| 2018 FY | -20.5 Million EUR | -78.66% |
| 2017 FY | -11.47 Million EUR | -144.79% |
| 2016 FY | 25.62 Million EUR | 540.28% |
| 2015 FY | -5.81 Million EUR | -126.2% |
| 2014 FY | 22.21 Million EUR | 71.7% |
| 2013 FY | 12.93 Million EUR | -51.21% |
| 2012 FY | 26.52 Million EUR | 197.71% |
| 2011 FY | 8.9 Million EUR | 64.57% |
| 2010 FY | 5.41 Million EUR | -5.58% |
| 2009 FY | 5.73 Million EUR | -54.33% |
| 2008 FY | 12.55 Million EUR | 1918.17% |
| 2007 FY | 622 Thousand EUR | -73.62% |
| 2006 FY | 2.35 Million EUR | 46.55% |
| 2005 FY | 1.6 Million EUR | 372.25% |
| 2004 FY | -591 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 99.925% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 99.964% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 99.912% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 115.469% |
| Novartis AG | 9.76 Billion USD | 99.937% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 100.0% |